PubMed Health⌕ Search

Biomedical subjects

J Collignon-Brach

Publications and source records attributed to J Collignon-Brach.

At least 19 recordsLinked to original sources
PubMed1992

Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma.

Timolol (TIM) and betaxolol (BET) were evaluated for their effects on both intraocular pressure and retinal sensitivity as determined from visual fields in a randomized two-year parallel study in 20 patients with primary open-angle glaucoma. All treatments were twice-daily in both eyes. TIM was more effective than BET as an ocular hypotensive agent throughout the two year period. With regard to retinal sensitivity as measured by automated visual fields, there was a decrease in retinal sensitivity in the first six months in the TIM and BET treatment groups by 0.5-0.6 dB, and 0.2-0.3 dB, respectively. However, at the one and two year visits, retinal sensitivity increased 0.8-0.9 dB in the BET treatment group only. It appears that ocular hypotensive efficacy may not relate to retinal sensitivity within a period of two years or less in patients with mildly to moderately elevated intraocular pressure. Further work may reveal the reliability of this observation, and its clinical relevance.

Aged↗
PubMed1990

[Primary open-angle glaucoma. Effects of an eyedrop combining timolol and pilocarpine on the ocular pressure].

In a limited group of open angle glaucoma patients treated twice daily with timoptol 0.5% and having by this treatment a mean intra-ocular pressure of 21-22 mmHg, the association of timoptol 0.5% with pilocarpine 2% respectively, lowered the intra-ocular pressure to an average of 17.8 mmHg and 16.6 mmHg after one and three weeks of continuous treatment. For this study, the patients have been divided into 3 groups: A group treated with timoptol 0.5% alone throughout the 49 days of the study. A group treated with timoptol 0.5%-pilocarpine 2% (timpilo 2) from day 21 to day 49. A final group treated with timoptol 0.5% until day 21 and then with timoptol 0.5%-pilocarpine 4% (timpilo 4) through out day 49. These patients stopped the treatment before the end of the study. Intra-ocular pressures were measured on days 0, 21 and 49. We found a higher drop of pressure (-4.8 mmHg) in the timpilo 2 group than in the timoptol 0.5% group (-1 mmHg) before instillation as well as 2 hours afterwards (-5.25 mmHg and -2 mmHg respectively). The secondary local effects were due to miotics agents. The secondary systemic effects were those inherent to beta-blockers. These results are comparable with a multicentric study of 220 patients, therefore statistically significant.

Aged↗
PubMed1984

Corneal endothelial cell density in acute angle-closure glaucoma.

The endothelial cell density of 44 eyes after an acute attack of angle-closure glaucoma is statistically lower than the cellular density of 174 control eyes. The decrease in endothelial cell density increases the risk of edematous corneal dystrophy, more specially after surgery (e.g. cataract extraction). The modifications in corneal endothelial cell density are compared with the alterations of the iris after a crisis of angle-closure glaucoma.

Acute Disease↗
PubMed1982

Biometric study of the disc cup in open-angle glaucoma.

Stereoscopic and photogrammetric study of the disc cup in open-angle glaucoma reveals several morphological changes. The ovalisation of the cup, upwards, downwards or on the temporal side, appears early. It can be detected at the onset of the disease, even in the absence of visual field defects. It results in a localised thinning of the nervous rim, which is a characteristic sign of beginning glaucoma, but the depth of the cup is not increased even when perimetry already reveals important defects. The aim of this paper is to study, on the one hand, the morphological changes of the disc cup and on the other, the functional defects in open-angle glaucoma, and then to compare the results of the investigations.

Adult↗
PubMed1981

[Comparative clinical study of metoprolol and timolol (author's transl)].

Timolol is a non-specific beta-blocking agent acting on both beta 1 and beta 2 receptors while metoprolol is a specific beta 1 blocking agent. Both timolol and metoprolol decrease intraocular pressure by reducing aqueous humor secretion without increasing facility of outflow. They have both similar short and long term efficacy which does not diminish even after several months of use. Generally, there are adequate to treat glaucoma without perimetric changes, while treatment of glaucoma with functional defects requires their association with miotics. When blocking beta 1 receptors, timolol causes marked constriction of bronchi and peripheral vessels. Hence, it is contraindicated in bronchial asthma and ischemic optic neuropathy. This is not the case with metoprolol, which does not block beta 2 receptors.

Glaucoma↗
PubMed1980

[Treatment of primary closed angle glaucoma].

Surgery is the treatment of choice in angle closure glaucoma. Exceptions to this rule are rare. Peripheral iridectomy is the operation in reversible forms: asymptomatic forms, drug normalized attacks without anatomic alterations of the anterior segment, and when both eyes have the same biometry. Trabeculectomy is the treatment of all irreversible forms: attacks that are not controlled even with intensive medical management and subacute forms that progress to chronic angle closure glaucoma. Indication for combined cataract-trabeculectomy surgery are discussed in the text.

Acute Disease↗
PubMed1978

[Atenolol: its effects on pressure in open-angle glaucoma].

1. Instillation of 2 drops of 4% solution of atenolol decreases the ocular pressure in open angle glaucoma. 2. In 12 glaucomatous patients treated as in-patients, 4 daily instillations of 4% solution lower the average tension of the group below 20-22 mm Hg day and night. 3. The tensionnal effects of 4 or 6 daily instillations on out-patients seems to be less effective. 4. The hypotensive effects of atenolol, on some of the patients at least, decreases during the second month of uninterrupted treatment. However, the response to a single dose remains constant even after a long term treatment. 5. Treatment with atenolol is remarkably well tolerated. It does not provoke either local or general side effect. 6. Although the combination of atenolol and myotics or carbonic anhydrase inhibitors produces an additive pressure lowering effect this results in a loss of the advantages of atenolol with regard to absence of undesirable pharmacological effects.

Atenolol↗